The effects of the HbA1c tests on diabetic patients

Dulaglutide 1.5mg along with sulfonyurea seems to be important and highly effective than the sulfonylurea alone when it comes to lowering the HbA1c in diabetic patients must after twenty four weeks of the treatment. This is in relation to the newest report from the AWARD- 8 trial showed at the World Diabetes Congress. This was the preliminary study when it comes to checking the efficiency of the dulaglutide against the placebo on a history of sulfonylurea monotherapy. The outcomes were very precise with some information from the clinical trials made with dulaglutide program with conforming to glucose control with 1.3% between the group differences.  So, while the learning is ongoing and important, it was not unexpected according to a researcher.

Moreover, it is of the interest to check how the history therapy may be influential in terms of the effects on the weight and hypoglycemia. This part 3, randomized, blinded, placebo study is compared to the effectiveness and safety in around 299 patients with type-2 diabetes and baseline HbA1c of 8.4%. During the primary end point of 24 weeks, the dulaglutide along with the sulfonylurea was seen to have the best effect to the sulfonylurea along with the placebo for the HbA1c lessen from the baseline. This study was made in relation to the patients in the dulaglutide plus and sulfonylurea arm achieved the HA1c of not lower tan 7% when compared with the sulfonylurea plus placebo of around 18%.

How the study went on

There are researchers who also went on in studying and they found out that the dulaglutide plus are also reduced in fasting serum glucose levels when compared with the sulfonylurea plus placebo that is if the dulaglutide is mixed with sulfonylurea. They usually conveyed opposing events were GI linked with some other studies. There were no other cases of pancreatitis or pancreatic cancer in both groups. Just as expected, more patients who went through the treatment of the dulaglutide plus which is a sulfonylurea arm experienced some episodes of hypoglycemia when compared with those who went through the sulfonylurea alone, even if the entire incidence of documented symptomatic hypoglycemia was around 11% in the dulaglutide arm.

However, there are side effects on record that are all GI related with nature, around 20% of the patients suffer from nausea, eructation and diarrhea. This is just related; however, it is essential to highlight the GI side effects that were mild to moderate in some patients. On the other hand, there were no suspected cases of chronic hypoglycemia in both groups. As a secondary endpoint of the study, the dulaglutide plus a sulfonylurea was linked with the reduction of weight from the baseline even if the through the variation when compared with a sulfonylurea along with the placebo didn’t research any of the statistical significance.  The findings simply affirm the agent is very effective and it can be tolerated as an addition to the sulfonylurea therapy according to a doctor.